D. Kontoyiannis, R. Hachem, R. Lewis
Jul 15, 2003
Citations
9
Influential Citations
274
Citations
Quality indicators
Journal
Cancer
Abstract
Caspofungin (CAS) as salvage therapy for refractory invasive aspergillosis (IA) had a response rate of 45% among a heterogeneous group of patients. The use of CAS with other agents is appealing given its unique mechanism of action. Therefore, the authors retrospectively evaluated the efficacy and toxicity of CAS plus liposomal amphotericin B (LipoAMB) in patients with documented (definite or probable) or possible IA.